Abstract:Ethnopharmacological relevance: Ermiao wan (2 MW) is one of the most frequently prescription in traditional Chinese medicine (TCM) to treat hyperuricemia. Sanmiao wan (3 MW) and Simiao wan (4 MW), two modified Ermiao wan, also show good clinical effects in the treatment of gout and hyperuricemia. However, their uric acid lowering effects and potential action mechanism still need to be systematically investigated. Aim of the study: The aim of present study was to analyze and compare the uric acid-lowering effects of 2 MW, 3 MW and 4 MW in rat with high fructose combined with potassium oxonate (HFCPO)-induced hyperuricemia and their possible mechanisms through plasma metabolomics methods. Materials and methods: HFCPO-induced hyperuricemia rat model was established to evaluate the therapeutic effects of Ermiao wan categorized formulas (ECFs, including 2 MW, 3 MW and 4 MW). Body weight, blood uric acid, creatinine, urine uric acid and urine creatinine levels and histopathological parameters of rats were assessed. Plasma untargeted metabolomics based on ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS) was established to collect the metabolic profiles of rats and explore the metabolic changes that occurred after each ECFs treatment. Results: Oral administration of ECFs could decrease the level of blood uric acid, creatinine and increase the level of urine uric acid and urine creatinine in varying degrees, and alleviated hepatocyte steatosis and atrophy and degeneration of glomerulus, vacuolar degeneration of renal tubular epithelial cells in HFCPO-induced hyperuricemia rats. Plasma untargeted metabolomics analysis showed that significant alterations were observed in metabolic signatures between the HFCPO-induced hyperuricemia group and control group. Thirty five potential biomarkers in rat plasma were identified in the screening by principal component analysis (PCA), partial least squares discrimination analysis (PLS-DA) and orthogonal partial least squares discrimination analysis (OPLS-DA). Differential metabolites related to hyperuricemia, including acylcarnitines and amino acid related metabolites, were further used to indicate relevant pathways in hyperuricemia rats, including tryptophan metabolism, arginine biosynthesis, purine metabolism, arginine and proline metabolism, beta-alanine metabolism, citrate cycle (TCA cycle), glycerophospholipid metabolism and linoleic acid metabolism. 2 MW, 3 MW and 4 MW could invert the pathological process of hyperuricemia to varying degrees through in part regulating the perturbed lipid metabolic pathway. 4 MW were better than 2 MW and 3 MW in the intervention of the disordered tricarboxylic acid metabolism and purine metabolism caused by hyperuricemia. Conclusion: In summary, ECFs treatment could effectively alleviate symptoms of hyperuricemia and regulate metabolic disorders in HFCPO-induced hyperuricemia rats.

Antihyperuricemic Effect of Tuna Protein Hydrolysate and Derived Products after in Vitro Digestion or Maillard Reaction on Oteracil Potassium‐induced Hyperuricemia Rats

In Vivo Anti-Hyperuricemic and Xanthine Oxidase Inhibitory Properties of Tuna Protein Hydrolysates and Its Isolated Fractions.

Protective effects of tuna meat oligopeptides (TMOP) supplementation on hyperuricemia and associated renal inflammation mediated by gut microbiota

Identification of Hyperuricemia Alleviating Peptides from Yellow Tuna Thunnus albacares

Study on the Antagonism Effect of Prunus Mume Extracts against Yeast Extract Induced Hyperuricemia in Mice

Ameliorative action of "daitongxiao" against hyperuricemia includes the "uric acid transporter group"

Antihyperuricemic Effect of Mangiferin Aglycon Derivative J99745 by Inhibiting Xanthine Oxidase Activity and Urate Transporter 1 Expression in Mice.

Anti-hyperuricemic peptides derived from bonito hydrolysates based on in vivo hyperuricemic model and in vitro xanthine oxidase inhibitory activity.

Honey Mushroom, Armillaria mellea (Agaricomycetes) and Its Fermentation Products Target Regulation of OAT1/OAT3 Proteins to Reduce Hyperuricemia in Mice

Suppressive Effect of Huzhentongfeng on Experimental Gouty Arthritis: an in Vivo and in Vitro Study.

A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective

In Vitro and in Silico Xanthine Oxidase Inhibitory Activity of Selected Phytochemicals Widely Present in Various Edible Plants.

Alleviation of Hyperuricemia by Strictinin in AML12 Mouse Hepatocytes Treated with Xanthine and in Mice Treated with Potassium Oxonate

Novel Xanthine Oxidase Inhibitory Peptides Derived from Whey Protein: Identification, in Vitro Inhibition Mechanism and in Vivo Activity Validation

Effect of Different Buffer Systems on the Xanthine Oxidase Inhibitory Activity of Tuna (katsuwonus Pelamis) Protein Hydrolysate.

Untargeted metabolomics reveal the therapeutic effects of Ermiao wan categorized formulas on rats with hyperuricemia

Screening of Xanthine Oxidase Inhibitor from Selected Edible Plants and Hypouricemic Effect of Rhizoma Alpiniae Officinarum Extract on Hyperuricemic Rats

Xanthine oxidase inhibitory activity and antihyperuricemic effect of Moringa oleifera Lam. leaf hydrolysate rich in phenolics and peptides

The Alleviating Effects and Mechanisms of Lactiplantibacillus Plantarum MC14 on Hyperuricemia in Mice

Recent Advances in the Application of Foodborne Substances in Hyperuricemia

Xanthine Oxidase Inhibitory Peptides from Larimichthys polyactis: Characterization and In Vitro/In Silico Evidence